Probucol
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 4,4'-[propane-2,2-diylbis(thio)]bis(2,6-di-tert-butylphenol) | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a611037 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 23288-49-5  |
| ATC code | C10AX02 |
| PubChem | CID 4912 |
| DrugBank | DB01599 |
| ChemSpider | 4743 |
| UNII | P3CTH044XJ |
| KEGG | D00476 |
| ChEMBL | CHEMBL608 |
| Synonyms | 2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol |
| Chemical data | |
| Formula | C31H48O2S2 |
| Mol. mass | 516.844 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Probucol is an anti-hyperlipidemic drug[1] initially developed in the treatment of coronary artery disease.
However, clinical trials were stopped after it was found that it may lower HDL in patients with a previous history of heart disease.
Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity.
[edit] Mechanism
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption.[2] Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.
It is believed to act at ABCA1.[3]
It also lowers levels of HDL.[4]
[edit] References
- ^ Yamamoto A (December 2008). "A Uniqe Antilipidemic Drug - Probucol" ([dead link]). J. Atheroscler. Thromb. 15 (6): 304–5. PMID 19075491. http://joi.jlc.jst.go.jp/JST.JSTAGE/jat/E621?from=PubMed.
- ^ "Probucol. Drugs.com web site. [1]
- ^ Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH (December 2004). "Probucol inhibits ABCA1-mediated cellular lipid efflux". Arterioscler. Thromb. Vasc. Biol. 24 (12): 2345–50. doi:10.1161/01.ATV.0000148706.15947.8a. PMID 15514211. http://atvb.ahajournals.org/cgi/pmidlookup?view=long&pmid=15514211.
- ^ Miida T, Seino U, Miyazaki O, et al. (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis 200 (2): 329–35. doi:10.1016/j.atherosclerosis.2007.12.031. PMID 18279878.
|
||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
